Ariad Pharmaceuticals’ stock plunged yesterday on news that the Cambridge company was suspending sales of its leukemia drug Iclusig because of concerns that patients taking it could suffer life-threatening blood clots. Shares dropped more than 44 percent to $2.20 on the Nasdaq stock exchange after federal regulators asked it to stop marketing the drug. Ariad first disclosed a higher rate of side effects related to blood clots Oct. 9. - See more at: http://bostonherald.com/business/healthcare/2013/10/ariad_shares_dive_as_drug_sale_halted#sthash.Quppx8o5.dpuf
Help employers find you! Check out all the jobs and post your resume.
